HK Stock MarketDetailed Quotes

01952 EVEREST MED-B

Watchlist
  • 46.500
  • -0.350-0.75%
Not Open Dec 20 16:08 CST
15.16BMarket Cap-13.14P/E (TTM)

About EVEREST MED-B Company

Everest Medicines is a late-clinical biopharmaceutical company dedicated to licensing, developing, and commercializing innovative therapies around the world, with the goal of addressing critical unmet medical needs in Greater China and other emerging Asia-Pacific markets. Our world-class clinical and regulatory teams, insight-driven business development engine, and integrated commercial platform enable us to accelerate the delivery of innovative new medicines to patients. Since our establishment in 2017, we have brought together eight promising clinical-stage drug candidates for oncology, immunology, cardio-renal diseases, and infectious diseases. We target these four treatment areas based on the severity of unmet medical needs, the size of the high-risk patient population, and the emergence of innovative products around the world.

Company Profile

Symbol01952
Company NameEVEREST MED-B
ISINKYG3224E1061
Listing DateOct 9, 2020
Issue Price55.00
Shares Offered63.55M share(s)
FoundedJul 14, 2017
Registered AddressCayman Islands
Chairmanwei fu
Secretaryxuxinliuqihua liu
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficePO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands
Head Office and Principal Place of Business5th Floor, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees520
MarketHong Kong motherboard
EmailIR@everestmedicines.com
Websitehttp://www.everestmedicines.com
Business Genting Xinyao Co., Ltd. is a biopharmaceutical company mainly engaged in R&D, clinical development, manufacturing and commercialization of innovative drugs and vaccines. The company has established a product pipeline across nephropathy, infectious and autoimmune diseases. The company's product line includes products such as TARPEYO (TARPEYO) for the treatment of nephropathy, and ijia (eracycline) for the treatment of infections including clinically common gram-negative bacteria, gram-positive bacteria, anaerobes, etc. The company operates in domestic and foreign markets.

Company Executives

  • Name
  • Position
  • Salary
  • wei fu
  • Presidencies, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members
  • --
  • yongqing luo
  • CEOs, Executive Director
  • 30.72M
  • ying he
  • President, Executive Director, Chief Financial Officer, Authorized Representative
  • 18.46M
  • jizhe cao
  • Non-executive Directors
  • --
  • honggang feng
  • Non-executive Directors
  • --
  • shidong jiang
  • Independent Non-Executive Director, Audit Committee Members, Remuneration Committee Members
  • 352.00K
  • yifan li
  • Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
  • 352.00K
  • haiyin xu
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members, Audit Committee Members
  • 352.00K
  • Jason Brown
  • Chief Business Development Officer
  • --
  • wei yang
  • Chief Scientific Officer
  • --
  • xuxin liu
  • Vice President of Corporate Affairs, Joint Company Secretary
  • --
  • qihua liu
  • Director of Corporate Services Department, Zhuojia Professional Business Co., Ltd., Joint Company Secretary, Authorized Representative
  • --
Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Pharmaceutical Companies
Pharmaceutical Companies
Intraday-0.05%